By Katherine Hamilton
The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review.
The FDA plans to take action on the application by Aug. 31, Capricor said Tuesday.
Shares rose 17% to $15.99 in pre-market trading Tuesday. They have nearly tripled in value over the past year.
Deramiocel is specifically being reviewed by the FDA to treat patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.
If the San Diego company gets FDA marketing approval for deramiocel regarding the treatment of Duchenne muscular dystrophy by Sept. 30, 2026, it would be eligible to receive a priority review voucher based on its previous receipt of a rare pediatric disease designation.
The FDA grants priority review to medicine applications that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 04, 2025 07:37 ET (12:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。